332 related articles for article (PubMed ID: 20850532)
1. Integrating multiple aspects of mitochondrial dynamics in neurons: age-related differences and dynamic changes in a chronic rotenone model.
Arnold B; Cassady SJ; VanLaar VS; Berman SB
Neurobiol Dis; 2011 Jan; 41(1):189-200. PubMed ID: 20850532
[TBL] [Abstract][Full Text] [Related]
2. Evidence for Compartmentalized Axonal Mitochondrial Biogenesis: Mitochondrial DNA Replication Increases in Distal Axons As an Early Response to Parkinson's Disease-Relevant Stress.
Van Laar VS; Arnold B; Howlett EH; Calderon MJ; St Croix CM; Greenamyre JT; Sanders LH; Berman SB
J Neurosci; 2018 Aug; 38(34):7505-7515. PubMed ID: 30030401
[TBL] [Abstract][Full Text] [Related]
3. The Interaction of Mitochondrial Biogenesis and Fission/Fusion Mediated by PGC-1α Regulates Rotenone-Induced Dopaminergic Neurotoxicity.
Peng K; Yang L; Wang J; Ye F; Dan G; Zhao Y; Cai Y; Cui Z; Ao L; Liu J; Zou Z; Sai Y; Cao J
Mol Neurobiol; 2017 Jul; 54(5):3783-3797. PubMed ID: 27271125
[TBL] [Abstract][Full Text] [Related]
4. Mic60/mitofilin overexpression alters mitochondrial dynamics and attenuates vulnerability of dopaminergic cells to dopamine and rotenone.
Van Laar VS; Berman SB; Hastings TG
Neurobiol Dis; 2016 Jul; 91():247-61. PubMed ID: 27001148
[TBL] [Abstract][Full Text] [Related]
5. Nicotinic receptor stimulation protects nigral dopaminergic neurons in rotenone-induced Parkinson's disease models.
Takeuchi H; Yanagida T; Inden M; Takata K; Kitamura Y; Yamakawa K; Sawada H; Izumi Y; Yamamoto N; Kihara T; Uemura K; Inoue H; Taniguchi T; Akaike A; Takahashi R; Shimohama S
J Neurosci Res; 2009 Feb; 87(2):576-85. PubMed ID: 18803299
[TBL] [Abstract][Full Text] [Related]
6. The interplay of neuronal mitochondrial dynamics and bioenergetics: implications for Parkinson's disease.
Van Laar VS; Berman SB
Neurobiol Dis; 2013 Mar; 51():43-55. PubMed ID: 22668779
[TBL] [Abstract][Full Text] [Related]
7. The effects of rotenone on TH, BDNF and BDNF-related proteins in the brain and periphery: Relevance to early Parkinson's disease.
Johnson ME; Zhou XF; Bobrovskaya L
J Chem Neuroanat; 2019 Apr; 97():23-32. PubMed ID: 30690135
[TBL] [Abstract][Full Text] [Related]
8. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage.
Sherer TB; Betarbet R; Stout AK; Lund S; Baptista M; Panov AV; Cookson MR; Greenamyre JT
J Neurosci; 2002 Aug; 22(16):7006-15. PubMed ID: 12177198
[TBL] [Abstract][Full Text] [Related]
9. Effect of centrophenoxine against rotenone-induced oxidative stress in an animal model of Parkinson's disease.
Verma R; Nehru B
Neurochem Int; 2009 Nov; 55(6):369-75. PubMed ID: 19375462
[TBL] [Abstract][Full Text] [Related]
10. The Effect of Neuronal CoQ
Millichap L; Turton N; Damiani E; Marcheggiani F; Orlando P; Silvestri S; Tiano L; Hargreaves IP
Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928331
[TBL] [Abstract][Full Text] [Related]
11. Mitochondrial dynamics in Parkinson's disease.
Van Laar VS; Berman SB
Exp Neurol; 2009 Aug; 218(2):247-56. PubMed ID: 19332061
[TBL] [Abstract][Full Text] [Related]
12. Mitochondrial complex inhibitors preferentially damage substantia nigra dopamine neurons in rat brain slices.
Bywood PT; Johnson SM
Exp Neurol; 2003 Jan; 179(1):47-59. PubMed ID: 12504867
[TBL] [Abstract][Full Text] [Related]
13. Phenothiazine normalizes the NADH/NAD
Tapias V; McCoy JL; Greenamyre JT
Redox Biol; 2019 Jun; 24():101164. PubMed ID: 30925294
[TBL] [Abstract][Full Text] [Related]
14. Mfn2 protects dopaminergic neurons exposed to paraquat both in vitro and in vivo: Implications for idiopathic Parkinson's disease.
Zhao F; Wang W; Wang C; Siedlak SL; Fujioka H; Tang B; Zhu X
Biochim Biophys Acta Mol Basis Dis; 2017 Jun; 1863(6):1359-1370. PubMed ID: 28215578
[TBL] [Abstract][Full Text] [Related]
15. Pretreatment with near-infrared light via light-emitting diode provides added benefit against rotenone- and MPP+-induced neurotoxicity.
Ying R; Liang HL; Whelan HT; Eells JT; Wong-Riley MT
Brain Res; 2008 Dec; 1243():167-73. PubMed ID: 18848925
[TBL] [Abstract][Full Text] [Related]
16. A highly reproducible rotenone model of Parkinson's disease.
Cannon JR; Tapias V; Na HM; Honick AS; Drolet RE; Greenamyre JT
Neurobiol Dis; 2009 May; 34(2):279-90. PubMed ID: 19385059
[TBL] [Abstract][Full Text] [Related]
17. Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline.
Casarejos MJ; Menéndez J; Solano RM; Rodríguez-Navarro JA; García de Yébenes J; Mena MA
J Neurochem; 2006 May; 97(4):934-46. PubMed ID: 16573651
[TBL] [Abstract][Full Text] [Related]
18. Dynamin-related protein 1: A protein critical for mitochondrial fission, mitophagy, and neuronal death in Parkinson's disease.
Feng ST; Wang ZZ; Yuan YH; Wang XL; Sun HM; Chen NH; Zhang Y
Pharmacol Res; 2020 Jan; 151():104553. PubMed ID: 31760107
[TBL] [Abstract][Full Text] [Related]
19. Drp1, a potential therapeutic target for Parkinson's disease, is involved in olfactory bulb pathological alteration in the Rotenone-induced rat model.
Zhang X; Huang W; Shao Q; Yang Y; Xu Z; Chen J; Zhang X; Ge X
Toxicol Lett; 2020 Jun; 325():1-13. PubMed ID: 32088201
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotective effect of asiatic acid on rotenone-induced mitochondrial dysfunction and oxidative stress-mediated apoptosis in differentiated SH-SYS5Y cells.
Nataraj J; Manivasagam T; Justin Thenmozhi A; Essa MM
Nutr Neurosci; 2017 Jul; 20(6):351-359. PubMed ID: 26856988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
